2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
10
Neoplasms
6
Lymphoma, Non-Hodgkin
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm Metastasis
4
Lymphoma
4
Leukemia
4
Hodgkin Disease
4
Burkitt Lymphoma
4
Breast Neoplasms
4
Vomiting
3
Prostatic Neoplasms
3
Lymphoma, B-Cell
3
Lung Neoplasms
3
Leukemia, Hairy Cell
3
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Stomatitis
2
Stomach Neoplasms
2
Rectal Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Nausea
2
Myelodysplastic Syndromes
2
Mucositis
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Interventions
ofatumumab
1
ocrelizumab
1
obinutuzumab
1
ibritumomab tiuxetan
1
Rituximab
1
Paclitaxel
1
Diphenhydramine
1
Cetirizine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Oncology Patients Receiving Chemotherapy
×
Diphenhydramine
×
Clear all
NCT04189588
2023-10-06
versus
TerSera Therapeutics LLC
Phase 2
Completed
34 enrolled
11 charts